Preferred Label : Lenalidomide;

MeSH definition : A phthalimide and piperidone derivative that has immunomodulatory and antiangiogenic properties. It is used for the treatment of transfusion-dependent anemia in MYELODYSPLASTIC SYNDROMES, and for the treatment of MULTIPLE MYELOMA, and relapsed or refractory MANTLE CELL LYMPHOMA.;

MeSH synonym : 3-(4-Amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione; 2,6-Piperidinedione, 3-(4-amino-1,3-dihydro-1-oxo-2H- isoindol-2-yl)-; IMiD3 Cpd;

MeSH hyponym : CC5013; CC-5013; Revimid;

MeSH Related Number : 191732-72-6 (Lenalidomide);

Wikipedia link : https://en.wikipedia.org/wiki/Lenalidomide;

UNII : F0P408N6V4;

Details


Main resources

You can consult :

A phthalimide and piperidone derivative that has immunomodulatory and antiangiogenic properties. It is used for the treatment of transfusion-dependent anemia in MYELODYSPLASTIC SYNDROMES, and for the treatment of MULTIPLE MYELOMA, and relapsed or refractory MANTLE CELL LYMPHOMA.

https://ansm.sante.fr/tableau-marr/lenalidomide
2024
false
false
false
France
French
risk management
pregnancy
contraception
lenalidomide
multiple myeloma
lymphoma, mantle-cell
teratogens
continuity of patient care
drug monitoring
clinical chemistry tests
myelodysplastic syndromes
guidelines for drug use
popular works
venous thromboembolism
Tumor Flare Reaction
neoplasms
Chemical and Drug Induced Liver Injury
angiogenesis inhibitors
angiogenesis inhibitors
thalidomide
thalidomide
thalidomide
Lenalidomide
Lenalidomide

---
https://www.ema.europa.eu/en/medicines/human/EPAR/lenalidomide-krka-dd-novo-mesto
2021
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
Lenalidomide
Lenalidomide
lenalidomide
angiogenesis inhibitors
angiogenesis inhibitors
drugs, generic
multiple myeloma
lymphoma, follicular
adult
antineoplastic combined chemotherapy protocols
administration, oral
immunologic factors
immunologic factors
aged
drug interactions
pregnancy
breast feeding
Progression-Free Survival
survival analysis
drug evaluation, preclinical
myelodysplastic syndromes
lymphoma, mantle-cell
R-Squared Regimen
RVD Regimen
Dexamethasone/Lenalidomide Regimen

---
https://www.ema.europa.eu/en/medicines/human/EPAR/lenalidomide-krka
2021
false
false
false
Netherlands
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
Lenalidomide
Lenalidomide
lenalidomide
angiogenesis inhibitors
angiogenesis inhibitors
drugs, generic
multiple myeloma
lymphoma, follicular
adult
antineoplastic combined chemotherapy protocols
administration, oral
immunologic factors
immunologic factors
aged
drug interactions
pregnancy
breast feeding
Progression-Free Survival
survival analysis
drug evaluation, preclinical
RVD Regimen
Dexamethasone/Lenalidomide Regimen
R-Squared Regimen

---
https://www.ema.europa.eu/en/medicines/human/EPAR/lenalidomide-krka-dd
2021
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
Lenalidomide
Lenalidomide
lenalidomide
angiogenesis inhibitors
angiogenesis inhibitors
drugs, generic
multiple myeloma
lymphoma, follicular
adult
antineoplastic combined chemotherapy protocols
administration, oral
immunologic factors
immunologic factors
aged
drug interactions
pregnancy
breast feeding
Progression-Free Survival
survival analysis
drug evaluation, preclinical
myelodysplastic syndromes
Dexamethasone/Lenalidomide Regimen
R-Squared Regimen
RVD Regimen

---
https://www.ema.europa.eu/en/medicines/human/EPAR/lenalidomide-mylan
2021
false
false
false
Netherlands
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
Lenalidomide
Lenalidomide
multiple myeloma
lymphoma, follicular
drugs, generic
adult
aged
antineoplastic combined chemotherapy protocols
administration, oral
immunologic factors
immunologic factors
drug interactions
pregnancy
breast feeding
lenalidomide
drug evaluation, preclinical
Dexamethasone/Lenalidomide Regimen
RVD Regimen
R-Squared Regimen

---
https://www.has-sante.fr/jcms/p_3213001/fr/revlimid
2020
false
false
false
France
lenalidomide
administration, oral
insurance, health, reimbursement
treatment outcome
adult
lymphoma, follicular
evaluation of the transparency committee
Lenalidomide

---
https://www.has-sante.fr/jcms/p_3167441/fr/revlimid
2020
false
false
false
France
lenalidomide
treatment outcome
insurance, health, reimbursement
multiple myeloma
antineoplastic agents
immunologic factors
administration, oral
adult
evaluation of the transparency committee
Lenalidomide

---
https://www.has-sante.fr/jcms/p_3181646
2020
France
evaluation of the transparency committee
revlimid
Lenalidomide

---
https://www.has-sante.fr/jcms/p_3180072
2020
France
evaluation of the transparency committee
revlimid
Lenalidomide

---
https://www.pharmactuel.com/index.php/pharmactuel/article/view/1190
2018
false
false
false
false
Canada
French
critical appraisal or critical reading
Acne fulminans
daratumumab
data collection
multiple myeloma
Myeloma
Induced fracture
dexamethasone
intractable
Myeloma
therapeutics
treaties
combined
multiple myeloma
international cooperation
antibodies, monoclonal
thalidomide
Lenalidomide

---
https://dumas.ccsd.cnrs.fr/dumas-01964255/document
2018
France
dissertations, academic
therapeutics
Myeloma
Physicians
has patient
central
Chemotherapy
moving and lifting patients
dexamethasone
chemotherapy
general practice
multiple myeloma
patient-centered care
health
chemotherapy, nos
case management
multiple myeloma
general practitioners
Myeloma
thalidomide
Lenalidomide

---
https://www.ema.europa.eu/en/medicines/human/EPAR/lenalidomide-accord
2018
false
United Kingdom
English
French
syndication feed
drugs, generic
antineoplastic combined chemotherapy protocols
drug approval
europe
drug interactions
pregnancy
breast feeding
treatment outcome
drug evaluation
antineoplastic agents
drug therapy, combination
multiple myeloma
adult
thalidomide
lenalidomide
antineoplastic agents
drug evaluation
summary of product characteristics
package leaflet
Lenalidomide
Lenalidomide

---
http://www.has-sante.fr/portail/jcms/c_2746192/fr/revlimid-myelome-multiple
http://www.has-sante.fr/portail/jcms/c_2746192/fr/revlimid-lenalidomide-immunosuppresseur-myelome-multiple
2017
false
false
false
false
France
French
administration, oral
adult
antineoplastic combined chemotherapy protocols
survival analysis
treatment outcome
teratogens
lenalidomide
evaluation of the transparency committee
guidelines for drug use
immunosuppressive agents
immunosuppressive agents
orphan drug production
continuity of patient care
risk management
pregnancy
dexamethasone
multiple myeloma
thalidomide
thalidomide
thalidomide
Lenalidomide
Lenalidomide

---
http://www.has-sante.fr/portail/jcms/c_2751879/fr/revlimid-lcm
https://www.has-sante.fr/portail/jcms/c_2751879/fr/revlimid-lenalidomide-immunosuppresseur
2017
false
false
false
France
French
evaluation of the transparency committee
treatment outcome
administration, oral
antineoplastic agents
lenalidomide
lymphoma, mantle-cell
Refractory Mantle Cell Lymphoma
Recurrent Mantle Cell Lymphoma
recurrence
adult
Progression-Free survival
guidelines for drug use
disease-free survival
thalidomide
thalidomide
Lenalidomide

---
http://www.omedit-normandie.fr/media-files/6996/guide-imid-v200417-v2.pdf
2017
false
false
false
France
French
guideline
patient safety
pharmacy service, hospital
ambulatory care
thalidomide
drug prescriptions
pomalidomide
risk management
teratogens
pregnancy
multiple myeloma
immunologic factors
immunologic factors
immunologic factors
thalidomide
lenalidomide
pomalidomide
thalidomide
Lenalidomide

---
http://www.e-cancer.fr/Expertises-et-publications/Catalogue-des-publications/Medicaments-immunomodulateurs-IMID-Thalidomide-Lenalidomide-Pomalidomide-Anticancereux-par-voie-orale-informer-prevenir-et-gerer-leurs-effets-indesirables
2016
false
false
false
France
French
thalidomide
Drug-Related side effects and adverse reactions
antineoplastic combined chemotherapy protocols
thalidomide
Drug-Related side effects and adverse reactions
administration, oral
antineoplastic agents
immunologic factors
lenalidomide
drug interactions
practice guideline
pomalidomide
pomalidomide
information dissemination
continuity of patient care
pregnancy
patient education as topic
thalidomide
Lenalidomide

---
http://www.e-cancer.fr/content/download/126023/1524677/file/Médicaments%20immunomodulateurs%20(imid).pdf
2015
false
false
false
France
French
guidelines for drug use
administration, oral
pomalidomide
lenalidomide
pomalidomide
thalidomide
thalidomide
thalidomide
antineoplastic agents
immunologic factors
continuity of patient care
information dissemination
hospital-physician relations
physician-patient relations
teratogens
contraception
pregnancy
drug interactions
practice guideline
Drug-Related side effects and adverse reactions
Lenalidomide

---
REVLIMID 2,5 mg, gélule - REVLIMID 5 mg, gélule - REVLIMID 10 mg, gélule
http://www.has-sante.fr/portail/jcms/c_1782547/fr/revlimid-lenalidomide-immunosuppresseur
2014
false
false
false
France
French
treatment outcome
lenalidomide
myelodysplastic syndromes
Transfusion dependent anemia
anemia
blood transfusion
administration, oral
Chromosome 5q Deletion Syndrome
orphan drug production
immunologic factors
evaluation of the transparency committee
guidelines for drug use
thalidomide
thalidomide
anemia, macrocytic
chromosome deletion
chromosomes, human, pair 5
Lenalidomide

---
http://www.has-sante.fr/portail/jcms/c_1782547/fr/revlimid
2014
false
false
false
France
French
evaluation of the transparency committee
administration, oral
lenalidomide
treatment outcome
myelodysplastic syndromes
5q minus myelodysplastic syndrome
Chromosome 5q Deletion Syndrome
anemia, macrocytic
orphan drug production
chromosomes, human, pair 5
chromosome deletion
thalidomide
thalidomide
anemia, macrocytic
Lenalidomide

---
http://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2013/37383a-fra.php
http://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2013/37385a-fra.php
2013
Canada
French
English
administration, oral
antineoplastic agents
lenalidomide
multiple myeloma
drug therapy, combination
Chemical and Drug Induced Liver Injury
hepatitis
hepatic insufficiency
acute disease
risk factors
pharmacovigilance note
patient education handout
Chemical and Drug Induced Liver Injury
thalidomide
Lenalidomide

---
https://www.ema.europa.eu/medicines/human/EPAR/Revlimid
2012
false
United Kingdom
English
French
syndication feed
Dexamethasone/Lenalidomide Regimen
RVD Regimen
treatment outcome
drug evaluation
antineoplastic agents
drug therapy, combination
multiple myeloma
adult
thalidomide
lenalidomide
antineoplastic agents
orphan drug production
drug evaluation
summary of product characteristics
package leaflet
Lenalidomide
Lenalidomide

---
http://www.has-sante.fr/portail/display.jsp?id=c_603077
http://www.has-sante.fr/portail/jcms/c_1260936/revlimid
http://www.has-sante.fr/portail/upload/docs/application/pdf/2012-06/revlimid_06062012_avis__ct11991.pdf
2012
France
French
antineoplastic agents
survival analysis
antineoplastic agents
administration, oral
thalidomide
multiple myeloma
capsules
lenalidomide
drug therapy, combination
treatment outcome
evaluation of the transparency committee
Lenalidomide
Lenalidomide

---
http://www.healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2012/14122a-fra.php
http://www.healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2012/14686a-fra.php
2012
Canada
French
English
pharmacovigilance note
popular works
lenalidomide
administration, oral
antineoplastic agents
thalidomide
immunologic factors
multiple myeloma
myelodysplastic syndromes
anemia
neoplasms
Lenalidomide

---
https://hpr-rps.hres.ca/reg-content/sommaire-motif-decision-detailOne.php?lang=fr&linkID=SBD00127
2011
false
false
false
Canada
drug information
lenalidomide
capsules
Lenalidomide

---
Nous contacter.
08/06/2024


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.